279 related articles for article (PubMed ID: 25204569)
21. Low expression of MN1 associates with better treatment response in older patients with de novo cytogenetically normal acute myeloid leukemia.
Schwind S; Marcucci G; Kohlschmidt J; Radmacher MD; Mrózek K; Maharry K; Becker H; Metzeler KH; Whitman SP; Wu YZ; Powell BL; Baer MR; Kolitz JE; Carroll AJ; Larson RA; Caligiuri MA; Bloomfield CD
Blood; 2011 Oct; 118(15):4188-98. PubMed ID: 21828125
[TBL] [Abstract][Full Text] [Related]
22. Increased DNA methylation of Dnmt3b targets impairs leukemogenesis.
Schulze I; Rohde C; Scheller-Wendorff M; Bäumer N; Krause A; Herbst F; Riemke P; Hebestreit K; Tschanter P; Lin Q; Linhart H; Godley LA; Glimm H; Dugas M; Wagner W; Berdel WE; Rosenbauer F; Müller-Tidow C
Blood; 2016 Mar; 127(12):1575-86. PubMed ID: 26729896
[TBL] [Abstract][Full Text] [Related]
23. Expression and prognosis analysis of
Zhang TJ; Zhang LC; Xu ZJ; Zhou JD
Aging (Albany NY); 2020 Jun; 12(14):14677-14690. PubMed ID: 32597790
[TBL] [Abstract][Full Text] [Related]
24. The clinical characteristics and prognostic significance of MN1 gene and MN1-associated microRNA expression in adult patients with de novo acute myeloid leukemia.
Xiang L; Li M; Liu Y; Cen J; Chen Z; Zhen X; Xie X; Cao X; Gu W
Ann Hematol; 2013 Aug; 92(8):1063-9. PubMed ID: 23515710
[TBL] [Abstract][Full Text] [Related]
25. MN1 overexpression is driven by loss of DNMT3B methylation activity in inv(16) pediatric AML.
Larmonie NSD; Arentsen-Peters TCJM; Obulkasim A; Valerio D; Sonneveld E; Danen-van Oorschot AA; de Haas V; Reinhardt D; Zimmermann M; Trka J; Baruchel A; Pieters R; van den Heuvel-Eibrink MM; Zwaan CM; Fornerod M
Oncogene; 2018 Jan; 37(1):107-115. PubMed ID: 28892045
[TBL] [Abstract][Full Text] [Related]
26. High expression of lymphoid enhancer-binding factor-1 (LEF1) is a novel favorable prognostic factor in cytogenetically normal acute myeloid leukemia.
Metzeler KH; Heilmeier B; Edmaier KE; Rawat VP; Dufour A; Döhner K; Feuring-Buske M; Braess J; Spiekermann K; Büchner T; Sauerland MC; Döhner H; Hiddemann W; Bohlander SK; Schlenk RF; Bullinger L; Buske C
Blood; 2012 Sep; 120(10):2118-26. PubMed ID: 22815426
[TBL] [Abstract][Full Text] [Related]
27. High expression of inositol 1,4,5-trisphosphate receptor, type 2 (ITPR2) as a novel biomarker for worse prognosis in cytogenetically normal acute myeloid leukemia.
Shi JL; Fu L; Wang WD
Oncotarget; 2015 Mar; 6(7):5299-309. PubMed ID: 25779662
[TBL] [Abstract][Full Text] [Related]
28. miR-3151 interplays with its host gene BAALC and independently affects outcome of patients with cytogenetically normal acute myeloid leukemia.
Eisfeld AK; Marcucci G; Maharry K; Schwind S; Radmacher MD; Nicolet D; Becker H; Mrózek K; Whitman SP; Metzeler KH; Mendler JH; Wu YZ; Liyanarachchi S; Patel R; Baer MR; Powell BL; Carter TH; Moore JO; Kolitz JE; Wetzler M; Caligiuri MA; Larson RA; Tanner SM; de la Chapelle A; Bloomfield CD
Blood; 2012 Jul; 120(2):249-58. PubMed ID: 22529287
[TBL] [Abstract][Full Text] [Related]
29. High bone marrow miR-19b level predicts poor prognosis and disease recurrence in de novo acute myeloid leukemia.
Zhang TJ; Lin J; Zhou JD; Li XX; Zhang W; Guo H; Xu ZJ; Yan Y; Ma JC; Qian J
Gene; 2018 Jan; 640():79-85. PubMed ID: 29032147
[TBL] [Abstract][Full Text] [Related]
30. Ectopic DNMT3B expression delays leukemogenesis.
Stanley RF; Steidl U
Blood; 2016 Mar; 127(12):1525-6. PubMed ID: 27013212
[TBL] [Abstract][Full Text] [Related]
31. High BAALC expression associates with other molecular prognostic markers, poor outcome, and a distinct gene-expression signature in cytogenetically normal patients younger than 60 years with acute myeloid leukemia: a Cancer and Leukemia Group B (CALGB) study.
Langer C; Radmacher MD; Ruppert AS; Whitman SP; Paschka P; Mrózek K; Baldus CD; Vukosavljevic T; Liu CG; Ross ME; Powell BL; de la Chapelle A; Kolitz JE; Larson RA; Marcucci G; Bloomfield CD;
Blood; 2008 Jun; 111(11):5371-9. PubMed ID: 18378853
[TBL] [Abstract][Full Text] [Related]
32. MicroRNA-29b induces global DNA hypomethylation and tumor suppressor gene reexpression in acute myeloid leukemia by targeting directly DNMT3A and 3B and indirectly DNMT1.
Garzon R; Liu S; Fabbri M; Liu Z; Heaphy CE; Callegari E; Schwind S; Pang J; Yu J; Muthusamy N; Havelange V; Volinia S; Blum W; Rush LJ; Perrotti D; Andreeff M; Bloomfield CD; Byrd JC; Chan K; Wu LC; Croce CM; Marcucci G
Blood; 2009 Jun; 113(25):6411-8. PubMed ID: 19211935
[TBL] [Abstract][Full Text] [Related]
33. Construction of a microRNA-mRNA Regulatory Network in
Esa E; Hashim AK; Mohamed EHM; Zakaria Z; Abu Hassan AN; Mat Yusoff Y; Kamaluddin NR; Abdul Rahman AZ; Chang KM; Mohamed R; Subbiah I; Jamian E; Ho CS; Lim SM; Lau PC; Pung YF; Zain SM
Genet Test Mol Biomarkers; 2021 Mar; 25(3):199-210. PubMed ID: 33734890
[No Abstract] [Full Text] [Related]
34. High IL2RA mRNA expression is an independent adverse prognostic biomarker in core binding factor and intermediate-risk acute myeloid leukemia.
Du W; He J; Zhou W; Shu S; Li J; Liu W; Deng Y; Lu C; Lin S; Ma Y; He Y; Zheng J; Zhu J; Bai L; Li X; Yao J; Hu D; Gu S; Li H; Guo A; Huang S; Feng X; Hu D
J Transl Med; 2019 Jun; 17(1):191. PubMed ID: 31171000
[TBL] [Abstract][Full Text] [Related]
35. Overexpression of miR-216b: Prognostic and predictive value in acute myeloid leukemia.
Zhang TJ; Wu DH; Zhou JD; Li XX; Zhang W; Guo H; Ma JC; Deng ZQ; Lin J; Qian J
J Cell Physiol; 2018 Apr; 233(4):3274-3281. PubMed ID: 28884855
[TBL] [Abstract][Full Text] [Related]
36. Incidence and prognostic influence of DNMT3A mutations in acute myeloid leukemia.
Thol F; Damm F; Lüdeking A; Winschel C; Wagner K; Morgan M; Yun H; Göhring G; Schlegelberger B; Hoelzer D; Lübbert M; Kanz L; Fiedler W; Kirchner H; Heil G; Krauter J; Ganser A; Heuser M
J Clin Oncol; 2011 Jul; 29(21):2889-96. PubMed ID: 21670448
[TBL] [Abstract][Full Text] [Related]
37. High expression levels of the ETS-related gene, ERG, predict adverse outcome and improve molecular risk-based classification of cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B Study.
Marcucci G; Maharry K; Whitman SP; Vukosavljevic T; Paschka P; Langer C; Mrózek K; Baldus CD; Carroll AJ; Powell BL; Kolitz JE; Larson RA; Bloomfield CD;
J Clin Oncol; 2007 Aug; 25(22):3337-43. PubMed ID: 17577018
[TBL] [Abstract][Full Text] [Related]
38. High Expression of CPT1A Predicts Adverse Outcomes: A Potential Therapeutic Target for Acute Myeloid Leukemia.
Shi J; Fu H; Jia Z; He K; Fu L; Wang W
EBioMedicine; 2016 Dec; 14():55-64. PubMed ID: 27916548
[TBL] [Abstract][Full Text] [Related]
39. Identification of novel molecular markers for prognosis estimation of acute myeloid leukemia: over-expression of PDCD7, FIS1 and Ang2 may indicate poor prognosis in pretreatment patients with acute myeloid leukemia.
Tian Y; Huang Z; Wang Z; Yin C; Zhou L; Zhang L; Huang K; Zhou H; Jiang X; Li J; Liao L; Yang M; Meng F
PLoS One; 2014; 9(1):e84150. PubMed ID: 24416201
[TBL] [Abstract][Full Text] [Related]
40. Expression and prognostic impact of lncRNAs in acute myeloid leukemia.
Garzon R; Volinia S; Papaioannou D; Nicolet D; Kohlschmidt J; Yan PS; Mrózek K; Bucci D; Carroll AJ; Baer MR; Wetzler M; Carter TH; Powell BL; Kolitz JE; Moore JO; Eisfeld AK; Blachly JS; Blum W; Caligiuri MA; Stone RM; Marcucci G; Croce CM; Byrd JC; Bloomfield CD
Proc Natl Acad Sci U S A; 2014 Dec; 111(52):18679-84. PubMed ID: 25512507
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
